Sunshine sector’s sunspot
After the initial hue and cry over the unauthorised clinical trials of a product in India, a television channel in France was reported to have carried a report. Prompt came enquiries from the local audience if the Indian company was selling any product there.

Rise of biologicals
The risk associated with the development of human antibodies and biologicals is typically lower than that with small molecule therapeutics where the probability of a product going into clinical development and its chance of making it to approval can be less than eight per cent. This lower risk is a function of their superior safety profile and target specificity.